Sustained Increase of HDL Cholesterol Over a 72-Week Period in HIV-Infected Patients Exposed to an Antiretroviral Regimen Including Lopinavir/Ritonavir
Authors:
Open Access
- 1 December 2008
- journal article
- other
- Published by SAGE Publications in Journal of the International Association of Physicians in AIDS Care
- Vol. 7 (6) , 311-316
Abstract
Metabolic disorders are a major concern during antiretroviral therapy, especially for their potential to increase cardiovascular disease risk. In a multicenter, prospective study conducted in patients exposed to an antiretroviral regimen including lopinavir boosted with ritonavir, an early and sustained increase of high-density lipoprotein cholesterol was observed over a 72-week period. This increase was positively correlated with the exposure to lopinavir/ritonavir during the first 24 weeks.Keywords
This publication has 12 references indexed in Scilit:
- The Safety and Efficacy of Switching Stavudine to Tenofovir DF in Combination with Lamivudine and Efavirenz in HIV-1—Infected Patients: Three-Year Follow–up After Switching TherapyHIV Research & Clinical Practice, 2007
- HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular EventsNew England Journal of Medicine, 2007
- Class of Antiretroviral Drugs and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2007
- CD4+ Count–Guided Interruption of Antiretroviral TreatmentNew England Journal of Medicine, 2006
- Mortality in the Highly Active Antiretroviral Therapy EraJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patientsAtherosclerosis, 2006
- The effect of low‐dose ritonavir monotherapy on fasting serum lipid concentrationsHIV Medicine, 2005
- Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factorsJournal of Antimicrobial Chemotherapy, 2005
- Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practiceJournal of Infection, 2004
- Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV InfectionNew England Journal of Medicine, 2002